Particle-induced pulmonary acute phase response correlates with neutrophil influx linking inhaled particles and cardiovascular risk

Saber, Anne Thoustrup; Lamson, Jacob Stuart; Jacobsen, Nicklas Raun; Ravn-Haren, Gitte; Hougaard, Karin Sørig; Nyendi, Allen Njimeri; Wahlberg, Pia; Madsen, Anne Mette; Jackson, Petra; Wallin, Håkan

Published in: PloS one.

Link to article, DOI: 10.1371/journal.pone.0069020

Publication date: 2013

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Particle-Induced Pulmonary Acute Phase Response Correlates with Neutrophil Influx Linking Inhaled Particles and Cardiovascular Risk

Anne Thoustrup Saber1, Jacob Stuart Lamson1, Nicklas Raun Jacobsen1, Gitte Ravn-Haren2, Karin Sørg Hougaard3, Allen Njimeri Nyendi1, Pia Wahlberg3, Anne Mette Madsen1, Petra Jackson1, Håkan Wallin1, 4, Ulla Vogel1, 5

1 The National Research Centre for the Working Environment, Copenhagen, Denmark, 2 National Food Institute, Technical University of Denmark, Søborg, Denmark, 3 Danish Technological Institute, Taastrup, Denmark, 4 Institute of Public Health, University of Copenhagen, Copenhagen, Denmark, 5 Department of Micro- and Nanotechnology, Technical University of Denmark, Lyngby, Denmark

Abstract

Background: Particulate air pollution is associated with cardiovascular disease. Acute phase response is causally linked to cardiovascular disease. Here, we propose that particle-induced pulmonary acute phase response provides an underlying mechanism for particle-induced cardiovascular risk.

Methods: We analysed the mRNA expression of Serum Amyloid A (Saa3) in lung tissue from female C57BL/6J mice exposed to different particles including nanomaterials (carbon black and titanium dioxide nanoparticles, multi- and single walled carbon nanotubes), diesel exhaust particles and airborne dust collected at a biofuel plant. Mice were exposed to single or multiple doses of particles by inhalation or intratracheal instillation and pulmonary mRNA expression of Saa3 was determined at different time points of up to 4 weeks after exposure. Also hepatic mRNA expression of Saa3, SAA3 protein levels in broncheoalveolar lavage fluid and in plasma and high density lipoprotein levels in plasma were determined in mice exposed to multiwalled carbon nanotubes.

Results: Pulmonary exposure to particles strongly increased Saa3 mRNA levels in lung tissue and elevated SAA3 protein levels in broncheoalveolar lavage fluid and plasma, whereas hepatic Saa3 levels were much less affected. Pulmonary Saa3 expression correlated with the number of neutrophils in BAL across different dosing regimens, doses and time points.

Conclusions: Pulmonary acute phase response may constitute a direct link between particle inhalation and risk of cardiovascular disease. We propose that the particle-induced pulmonary acute phase response may predict risk for cardiovascular disease.

Introduction

Inhalation of particles by air pollution, smoking and occupational exposure cause pulmonary inflammation and are risk factors for cardiovascular disease [1,2]. The mechanisms by which particles induce cardiovascular diseases are not well understood. It is a generally held view that the particle-induced pulmonary inflammation leads to release of cytokines into the circulation that triggers a liver-mediated acute phase response which, in turn, promotes cardiovascular disease [2–5].

The acute phase response is a systemic response to acute and chronic inflammatory states caused by a variety of factors including bacterial infections, trauma, and infarction [6]. Acute phase response and the accompanying inflammatory response are strongly associated to increased risk of cardiovascular disease in epidemiological studies [7–9]. For example periodontal pathogen infection and virus infections are associated with risk of cardiovascular disease [10,11]. Blood levels of the acute phase proteins C-Reactive Protein (CRP) and Serum Amyloid A (SAA) are among the strongest known risk factors for cardiovascular diseases in prospective studies [12]. An association between air pollution and CRP levels has been observed in large cross-sectional and prospective studies [13,14]. This indicates that particle-induced inflammation and acute phase response may be important for cardiovascular disease.

The acute phase response is characterised by up- and down regulation of blood levels of a variety of proteins, termed acute phase proteins, such as CRP, SAA and fibrinogen [6]. In mice,
Saα3 is expressed in various tissues including lung and liver whereas Saα1 and Saα2 are considered liver specific [15]. In humans, SAA3 is a pseudogene [16] and SAA1 and SAA2 are expressed both hepatically and extra-hepatically [17]. CRP is expressed to a very limited extent in mice [18].

We have previously demonstrated that inhalation and instillation of the carbon black nanoparticle Printex 90 (NanoCB), and the titanium dioxide nanoparticle UV-Titan L181 (NanoTiO2) induce long-lasting pulmonary inflammation [19–23]. Unexpectedly, this was not accompanied by a hepatic acute phase response [19,24]. In contrast, both pulmonary exposure to NanoCB and NanoTiO2 induced a strong pulmonary acute phase response [19,25,26]. Thus, instillation of NanoCB lead to increased gene expression of several acute phase genes including Saa3, Saa2, Saa1, Metallothionein 2 (Mti2), Ceruloplasmin (Cp), Metallothionein 1 (Mti1), Orosomucoid 2 (Osm2), Orosomucoid 1 (Osm1) and Complement component 3 (C3) 24 hours after exposure [25]. Pulmonary exposure to NanoTiO2 lead to increased expression of 44 acute phase genes including Saa1, Saa2, Saa3, C3, B2b, C-c motif chemokine 4 (Ccl4), C-C motif chemokine 17 (Ccl17), Chemokine (C-X-C motif) ligand 5 (Cxcl5), S100 calcium-binding protein A8 (S100a8), S100 calcium binding protein A9 (S100a9), and NF-kappa-B inhibitor alpha (Nfkbia) 24 hours after exposure with dose-dependency in both the number of differentially expressed acute phase genes and the observed expression fold [26]. For both particle exposures, Saα3 was the most differentially expressed gene in murine lung tissue with 65-fold increase following NanoCB deposition [25] and up to 100-fold increase following NanoTiO2 deposition [26], one day after intratracheal instillation of 162 μg of particles. Thus, we here use pulmonary Saα3 gene expression in lung tissue as a biomarker of pulmonary acute phase response because of the large dynamic range in Saα3 gene expression.

We hypothesize that pulmonary deposition of particles in the lung triggers long-lasting pulmonary induction of acute phase proteins including Saα3 followed by lung secretion of acute phase proteins including SAα3 into blood. We propose that pulmonary acute phase response may constitute a direct link between particle inhalation and risk of cardiovascular disease and that air pollution-induced cardiovascular disease may thus be a direct consequence of pulmonary secretion of acute phase proteins that are known to affect many aspects of homeostasis such as plaque progression [27–29] and endothelial function [30].

Methods

Ethics Statement

The experiments were approved by the Danish “Animal Experiments Inspectorate” and carried out following their guidelines for ethical conduct and care when using animals in research.

Mice

C57BL/CJ female mice M&B or BomTac from later Taconic Denmark were used.

The virgin mice were allowed to acclimatize for 2 weeks and the time-mated mice were received on gestation day 3 (day of plug GD1). All mice were given food (Altromin 1324) and water ad libitum. The mice were group housed in polypropylene cages with sawdust bedding and enrichment (removed during nursing) at controlled temperature 21±1°C and humidity 50±10% with a 12-h light:12-h dark cycle.

Particles

The following materials were used in this study: carbon black (NanoCB), titanium dioxide (NanoTiO2), diesel exhaust particles (DEP), multiwalled carbon nanotubes (MWCNT), single-walled carbon nanotubes (SWCNT1 and SWCNT2) and airborne dust collected at a biofuel facility (boiler room and straw storage). The NanoCB, Printex 90 was a gift from Degussa-Hüls, Germany. The NanoTiO2, UV-Titan L181 (Kemira Pigments, Finland) was a gift from Bohens Fabrikker Aps, Denmark. The DEP was a standard reference material (SRM) 2975 purchased from the National Institute of Standards and Technology, USA. The MWCNT was a gift from Mitsui, Japan. The SWCNT1 was purchased from Sigma, USA. The SWCNT2 was purchased from Thomas Swan, USA. Airborne dust was collected from a boiler room (Boiler dust) and a straw storage hall (Straw dust) at a biofuel plant as described previously [31].

Exposure of mice

The study consists of six parts. An overview of the studies is given in Table 1. Study 1 is part of a larger set-up in which mice were given a single intratracheal instillation of a range of different types of particles. We have previously reported inflammatory and DNA damaging effects in mice given NanoTiO2 [20,26] and NanoCB [20,21] from this set-up.

Study 3–6 consists of experiments with mice that we have reported of previously [20,22,23,31,32], and for which lung tissue in this study was reanalyzed for Saα3 mRNA expression.

Exposure by intratracheal instillation. The instillation procedure has been described in detail previously [20]. In brief, the mice were given either 18 μg, 54 μg or 162 μg of particles (corresponding to ca. 0.9, 2.8 and 8.4 mg/kg, respectively) by a single i.t. instillation or 4 multiple instillations. After exposure, tissue and BAL cells were for all studies prepared as described previously [32].

For study 1 characterization of NanoCB and NanoTiO2 in instillation vehicle have been published previously [20,53]. For the rest of the particles in study 1 (MWCNT, SWCNT1, SWCNT2), the average size of the materials in instillation vehicle were analyzed by Dynamic Light Scattering (DLS) and the shapes of the materials and the extent of agglomeration/aggregation in instillation vehicle were characterized by scanning electron microscopy (SEM). Electron microscopy was performed on both pristine CNTs and CNTs in instillation vehicle. However, SEM pictures of CNTs in vehicle were dominated by salt crystals from the saline solution (results not shown). SEM pictures of the dry CNTs are showed in Figure 1. SWCNT1 and SWCNT2 both appeared bundled, hampering assessment of dimensions. This was true both when evaluated as powders and in suspension for instillation. DLS measurements of the CNTs suspensions indicated the presence of agglomerates in the μm-range probably due to bundling of CNTs and sedimentation (results not shown). A detailed characterization of the particles from study 3–6 was reported previously [20,22,24,31]. Selected data are summarized in Table 1.

Exposure by inhalation. Mice exposed by inhalation were exposed in a 18 L nose-only exposure chamber as previously described [22,23,32]. In brief, the particles were aerosolized by a microfeeder with dispersion nozzle (Fraunhofer Institut für Toxikologie und Aerosolforschung, Hannover, Germany). The number of particles was measured by a condensation particle counter (TSI model 3022A). The particle concentration was measured periodically during exposure by weighing of filters.
Table 1. Overview of studies and nanomaterials.

<table>
<thead>
<tr>
<th>Study</th>
<th>Exposure way</th>
<th>Particles</th>
<th>Deposited dose (µg)</th>
<th>Declared particle size</th>
<th>Agglomerated size in inhalation aerosol or instillation suspension</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Intratracheal</td>
<td>NanoCB</td>
<td>18, 54, 162</td>
<td>14 nm</td>
<td>200 nm²</td>
<td>[20]</td>
</tr>
<tr>
<td></td>
<td>instillation</td>
<td>NanoTiO₂</td>
<td>18, 54, 162</td>
<td>17 nm</td>
<td>100 nm²</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>MWCNT</td>
<td>18, 54, 162</td>
<td>40-50 nm x 1-4 µm</td>
<td>ND²</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SWCNT₁</td>
<td>18, 54, 162</td>
<td>1.1 nm x 0.5-100µm</td>
<td>ND³</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SWCNT₂</td>
<td>18, 54, 162</td>
<td>0.8-1.7 nm ≤ 1 µm</td>
<td>ND³</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Intratracheal</td>
<td>MWCNT</td>
<td>18, 54, 128</td>
<td>40-50 nm x 1-4 µm</td>
<td>ND³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>instillation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Inhalation</td>
<td>NanoCB</td>
<td>75</td>
<td>14 nm</td>
<td>65 nm³</td>
<td>[32]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DEP</td>
<td>19⁹</td>
<td>1.62 µm³</td>
<td>215 nm³</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Inhalation</td>
<td>NanoTiO₂</td>
<td>73</td>
<td>17 nm</td>
<td>97 nm³</td>
<td>[19]</td>
</tr>
<tr>
<td>5</td>
<td>Inhalation</td>
<td>NanoCB</td>
<td>287</td>
<td>14 nm</td>
<td>310 nm (bimodal: 290 and 1500 nm²)</td>
<td>[22]</td>
</tr>
<tr>
<td>6</td>
<td>Intratracheal</td>
<td>Boiler dust</td>
<td>216</td>
<td>ND³</td>
<td>ND³</td>
<td>[31]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Storage dust</td>
<td>216</td>
<td>ND³</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Based on a deposition fraction similar to NanoTiO₂.² Mean diameter (number distribution) from National Institute of Standards and Technology, Certificate of Analysis, Standard Reference Material® 2975,² Geometric mean,³ Not determined,⁴ Hydrodynamic size. Study 2 was an additional experiment performed to obtain plasma from MWCNT instilled mice and control animals.

doi:10.1371/journal.pone.0069020.0001

Set-up of studies

**Study 1.** The set-up of the single intratracheal instillation of nanomaterials has been described in detail for the NanoCB and NanoTiO₂ [20]. The mice exposed to the three types of CNTs were exposed similarly. In brief, mice received a single intratracheal instillation of 18, 54 and 162 µg of NanoTiO₂, NanoCB, MWCNT, SWCNT₁ or SWCNT₂ and were evaluated 1, 3 and 28 days after intratracheal instillation. Particles were suspended by sonication in 0.9% NaCl MilliQ water containing 10% v/v acellular BAL from C57BL/6 mice. The BAL fluid was prepared by flushing unexposed mice twice to 0.6 ml 0.9% NaCl solution yielding approximately 1 ml of BAL fluid. Acellular BAL was prepared by centrifugation of BAL fluid at 400 g (10 min, 4°C). The particles (4.05 mg/ml) were sonicated using a 400 W Branson Sonifier S-450D (Branson Ultrasonics Corp., Danbury, CT, USA) equipped with a disruptor horn (Model number: 101-147-037). Total sonication time was 16 min, with alternating 10 s pulses and 10 s pauses at amplitude of 10% (8 min sonication in total).

**Study 2.** Because no plasma was saved from study 1 a supplementary study was performed similarly to study 1 to obtain plasma from mice intratracheally instilled with MWCNT and control vehicle. In a separate batch, blood was collected from groups of 3 C57BL/6 mice 3 days after instillation of a single dose of 18 µg, 54 µg, or 128 µg of MWCNT. Particle suspensions were prepared as described for study 1. The reason for the different highest dose (128 µg) was that these mice also were part of another study.

**Study 3.** The design of the repeated exposure to NanoCB and DEP has been described in detail elsewhere [24]. In brief, we exposed C57 BL/6j virgin mice by inhalation to 20 mg/m³ DEP, NanoCB or filtered air for 90 min on four consecutive days. The particle numbers of NanoCB and DEP were ca. 8.0×10⁵/cm³ and 9.5×10⁵/cm³, respectively. One hour after the last exposure the mice were killed and lungs were snap frozen in liquid nitrogen and stored at −80°C.

**Study 4.** The design of the repeated exposure to NanoTiO₂ has been described in detail elsewhere [23]. In brief, C57BL/6j time-mated mice were exposed by inhalation 1h/day to 42 mg/m³ NanoTiO₂ on gestation days 8–18. The particle number concentration was 1.70±0.20×10⁵/cm³. Mice that did not give birth (non-pregnant mice) were killed 5 days after the end of exposure and lungs were snap frozen in liquid nitrogen and stored at −80°C. Dams were killed 26–27 days after the last exposure (after end of lactation) and tissue was treated as described above.

**Study 5.** The design of the repeated exposure to NanoCB has been described in detail elsewhere [22]. In brief, C57BL/6j time-mated mice were exposed by inhalation to 42 mg/m³ NanoCB for 1 h/day on gestation days (GD) 8–18. The particle number concentration was 4.09±0.03×10⁵/cm³. Mouse with none or few offspring were killed 5 days after the end of exposure and lungs were snap frozen in liquid nitrogen and stored at −80°C. Dams with larger litters were killed 24–25 days after the end of exposure and tissue was treated as described previously.

**Study 6.** The design of the repeated exposure to boiler dust and storage dust has been described in detail elsewhere [31]. In brief, C57 BL/6j virgin mice were intratracheally instilled on four consecutive days with 54 µg µg of airborne dust collected at a biofuel plant in the straw storage hall or to dust collected in the boiler room (total dose 216 µg/animal). Control mice were exposed similarly to a 0.9% sodium chloride solution. Endpoints were evaluated 1 hour after last exposure. Lungs were snap frozen in liquid nitrogen and stored at −80°C.

**Saa3 mRNA expression analysis**

Hepatic and pulmonary RNA from the C57BL/6 was isolated as described previously [24]. cDNA was prepared from DNase
Saa3 gene expression was determined using real-time RT-PCR with 18S RNA as the reference gene as previously described [24]. In brief, each sample was run in triplicate on the ABI PRISM 7700 sequence detector (PE Biosystems, Foster City, CA, USA). 

Table 2. Normalised Saa3 mRNA levels in lung 1, 3 and 28 days after pulmonary exposure to nanomaterials by instillation (study 1).

<table>
<thead>
<tr>
<th>Particle</th>
<th>Dose (µg)</th>
<th>Day1</th>
<th>Day3</th>
<th>Day28</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0</td>
<td>26±7</td>
<td>23±9</td>
<td>22±7</td>
</tr>
<tr>
<td>NanoTiO2</td>
<td>18</td>
<td>47±6</td>
<td>25±9</td>
<td>23±7</td>
</tr>
<tr>
<td>54 µg</td>
<td>2254±1625</td>
<td>59±39</td>
<td>40±28</td>
<td></td>
</tr>
<tr>
<td>162 µg</td>
<td>9585±2529f</td>
<td>447±415f</td>
<td>122±98f</td>
<td></td>
</tr>
<tr>
<td>NanoCB</td>
<td>18</td>
<td>1631±1961f</td>
<td>190±206f</td>
<td>25±16</td>
</tr>
<tr>
<td>54 µg</td>
<td>6152±3580f</td>
<td>546±135f</td>
<td>109±96f</td>
<td></td>
</tr>
<tr>
<td>162 µg</td>
<td>7635±9200f</td>
<td>1176±3122±</td>
<td>487±4364±</td>
<td></td>
</tr>
<tr>
<td>MWCNT</td>
<td>18</td>
<td>1343±1224f</td>
<td>903±947f</td>
<td>173±78f</td>
</tr>
<tr>
<td>54 µg</td>
<td>3928±1946f</td>
<td>3496±4159f</td>
<td>643±588f</td>
<td></td>
</tr>
<tr>
<td>162 µg</td>
<td>2459±1503f</td>
<td>1407±9402f</td>
<td>1946±1031f</td>
<td></td>
</tr>
<tr>
<td>SWCNT1</td>
<td>18</td>
<td>1318±960f</td>
<td>137±88f</td>
<td>50±51</td>
</tr>
<tr>
<td>54 µg</td>
<td>1454±745f</td>
<td>306±195f</td>
<td>143±160f</td>
<td></td>
</tr>
<tr>
<td>162 µg</td>
<td>1616±1042f</td>
<td>627±398f</td>
<td>243±258f</td>
<td></td>
</tr>
<tr>
<td>SWCNT2</td>
<td>18</td>
<td>2431±2280f</td>
<td>50±13f</td>
<td>41±37</td>
</tr>
<tr>
<td>54 µg</td>
<td>9853±11063f</td>
<td>233±186f</td>
<td>105±58f</td>
<td></td>
</tr>
<tr>
<td>162 µg</td>
<td>3736±1886f</td>
<td>473±428f</td>
<td>395±331f</td>
<td></td>
</tr>
</tbody>
</table>

Saa3 mRNA levels were normalised to 18S and multiplied by 10^7. Mean±SD is shown. 

*p<0.05, **p<0.01, ***p<0.001, §data published previously [21].

doi:10.1371/journal.pone.0069020.g001

For Saa1 (Mm00656927_g1) and Sapos (Mm00488099_g1), TaqMan pre-developed reaction kits (Applied Biosystems, USA) were used. The sequences of the Saa3 primers and probe were: Saa3 forward: 5’ GGCTGGTGGCCTGAT3’, Saa3 reverse: 5’ TGGTCCATGCTCCGTGATTACGCA3’ and Saa3 probe: 5’ FAM –TCTGAAAGAGTCTGCGCATGCCGCT– TAMRA 3’. Target genes and 18S RNA levels were quantified in separate wells. The relative expression of the target gene was calculated by the comparative method 2^−ΔΔCt [34]. The average standard deviation on triplicates was 15%. The standard deviation on repeated measurements of the same sample (the control) in separate experiments was 25%, indicating that the day-to-day variation of the assay was 23%. The probes and primers have been validated and the assay was quantitative over a 256-fold range. Messenger RNA measurements were excluded if the 18S content fell outside the range in which the PCR was found to be quantitative defined by the validation experiments. Negative controls, where RNA had not been converted to cDNA, were included in each run.

SAA3 protein analysis

Plasma SAA3 and BALF SAA3 was measured by ELISA (Mouse Serum Amyloid A-3, Cat.#EZMSAA3-12K, Millipore) according to manufacturer’s instructions.

HDL, LDL and VLDL cholesterol concentrations

Lipoproteins were separated by density gradient ultracentrifugation for 18 h at 21°C using 150 µl of plasma according to Terpstra et al. [35]. Cholesterol concentration in lipoprotein fractions were determined on an automatic analyzer (Hitachi 912, Roche Diagnostics GmbH, Mannheim, Germany) using a commercially available kit (test kit # 14899232, Roche Diagnostics GmbH, Mannheim, Germany).
Statistical analysis

Data are expressed as mean±SD. The data were analysed by non-parametric two or three-way ANOVA with post-hoc Tukey-type multiple comparisons test for effects showing statistical significance in the overall ANOVA. The significance level was set to 0.05. The statistical analyses were performed in SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).

Results

Induction of pulmonary acute phase response was assessed by quantifying mRNA levels of the acute phase gene *Saa3* as a marker of acute phase response, as we have previously found that *Saa3* is the most differentially expressed gene following pulmonary exposure to nanoparticles [19,25].

Intratracheal instillation of nanomaterials

Pulmonary induction of the acute phase response was assessed for five different nanomaterials after a single intratracheal instillation (Study 1, Table 1). These nanomaterials were NanoTiO2 and NanoCB, a multiwalled carbon nanotube (MWCNT), and two SWCNT (SWCNT1, SWCNT2). Groups of 6 mice were exposed to doses of 18, 54 and 162 µg/animal and the mice were killed 1, 3 and 28 days after instillation. Twenty-two mice (controls) were instilled with the vehicle (10% mouse bronchoalveolar lavage fluid (BALF) in 0.9% NaCl) at each time point. Some of the results from NanoCB-instilled mice were published previously [20,21]. Results from NanoTiO2-instilled mice were also published previously [26], but *Saa3* mRNA levels were determined independently for the present study to ensure comparability between exposures.

Saa3 mRNA expression.

All particle exposures increased pulmonary *Saa3* mRNA expression in a time- and dose-dependent manner (Table 2). For all particles, the strongest response was seen at the early time points. The strongest response, a 600-fold increase in *Saa3* expression was observed 3 days after exposure to MWCNT. The highest dose of NanoTiO2 resulted in a 400-fold increase in *Saa3* mRNA expression in lung at day 1. At day 1, all instilled nanoparticles except for SWCNT1 increased mRNA expression of *Saa3* 100-fold or more. This may be compared to a 100-fold induction observed in liver after intraperitoneal injection of lipopolysaccharide [24]. *Saa3* expression was still significantly increased 28 days after exposure for all mice exposed to the highest dose of all the tested materials and for mice exposed to even the lowest dose of MWCNT. This indicates a long-lasting induction of acute phase response.

MWCNT induced the strongest acute phase response in lung, and mRNA expression of *Saa3* was therefore also assessed in liver. MWCNT exposure did not change *Saa3* expression in liver at any dose or time point (Figure 2B).

SAA3 protein levels in BALF and plasma.

We determined the SAA3 protein levels in BALF by ELISA in mice exposed to MWCNT, because this material strongly induced pulmonary but not the hepatic *Saa3* expression.
The day after exposure, SAA3 protein levels were higher in BALF from MWCNT instilled animals at all doses compared to vehicle instilled controls. No dose-response relationship was seen (Figure 2C). At day 3 and day 28, no statistically significant differences in SAA3 protein levels were detected in BAL.

We determined SAA3 protein in plasma from groups of 3 mice, 3 days after instillation of a single dose of 18 μg, 54 μg, or 128 μg of MWCNT in a separate study (Study 2). Two control groups of unexposed and vehicle exposed animals had similar plasma SAA3 levels. The highest dose of MWCNT instillation increased plasma levels of SAA3 (p<0.01). One mouse instilled with 54 μg presented with a very high level of SAA3 and was considered an outlier. If the outlier was excluded, a dose-dependent increase in plasma SAA3 levels was observed. Without the outlier, plasma levels of SAA3 were 1.4-fold (p<0.05), 1.9-fold (p<0.05) and 3.8-fold (p<0.01) higher in mice exposed to 18, 54 and 128 μg MWCNT, respectively, compared to vehicle instilled and unexposed controls (Figure 2D). The used anti SAA-3 antibody was raised against full length SAA-3. The cross-reactivity with SAA1 and SAA2 is unknown (Millipore, personal communication). The true difference in SAA3 level may therefore be larger if there is cross-reactivity to constitutively expressed SAA isoforms.

**HDL, LDL and VLDL levels.** SAA circulates in blood as a component of HDL, and the classic acute phase response is accompanied by a decrease in HDL-cholesterol [36]. We determined the concentrations of cholesterol in HDL, very low density lipoprotein (VLDL), and low density lipoprotein (LDL) in plasma from mice exposed to MWCNT (Study 2). The concentration of cholesterol in HDL in plasma from MWCNT exposed mice was decreased to ca. 50% at all doses (but not statistically significantly) compared to the HDL-cholesterol concentration of un-exposed and vehicle-exposed mice. The concentrations of cholesterol in VLDL and LDL were unaffected by exposure (results not shown).

The results indicate that pulmonary exposure to these nanomaterials induces pulmonary acute phase response that leads to systemic circulation of the acute phase protein SAA3. Pulmonary acute phase response may be a general response to pulmonary deposition of particles. We therefore also assessed pulmonary acute phase response in mice exposed to NanoTiO2, NanoCB and DEP by inhalation and other types of particles by pulmonary instillation.

**Nose-only inhalation of particles**

Saa3 mRNA levels were determined in lungs of mice exposed to 20 mg/m³ to DEP or NanoCB for 90 min for 4 consecutive days (Study 3). One hour after the last exposure Saa3 mRNA levels were 4.4-fold higher after exposure to NanoCB and 17.4-fold increased after exposure to DEP compared to control mice exposed to filtered air (p<0.001, Table 3). We have previously reported that in these same mice, hepatic mRNA expression of Saa3, Saa1, and Serum Amyloid P was unaffected by exposure [24].

Mice were exposed to 42 mg/m³ UV-Titan L181 (NanoTiO2) by whole body inhalation 1 h/day for 11 days (Study 4) [23]. Mice were killed 5 and 26–27 days after the last exposure. Pulmonary Saa3 mRNA was increased 24-fold after 5 days (p<0.0001) and 2.1-fold after 26–27 days (p<0.001) compared to controls exposed to filtered air. Saa3 mRNA levels in the liver were unaffected by exposure (Table 4). We found no difference in Saa1 or Sop mRNA expression in the liver at either time point and the pulmonary expression was below detection level (data not shown).

In a similar exposure set-up mice were exposed to 42 mg/m³ NanoCB 1 h/day for 11 consecutive days, also by whole body inhalation (Study 5) [22]. Exposed mice expressed 2.9-fold more pulmonary Saa3 mRNA (p<0.001) than controls exposed to filtered air five days after termination of exposure, and 1.9-fold (p<0.01) more after 24–25 days. At this time point, Saa3 mRNA was also increased 1.8-fold (p<0.05) in the liver (Table 4).

Thus, inhalation of particles also induced pulmonary acute phase response that was detectable one month after exposure.

**Intratracheal instillation of particles from a biofuel plant**

Pulmonary Saa3 expression was also determined in mice instilled with dust collected at a biofuel plant (Study 6) [31]. Mice were instilled intratracheally with airborne dust collected at a biofuel plant in the straw storage hall and in the boiler room. Endpoints were determined 1 h after the last instillation. Each mouse was instilled four times with 54 μg dust on four consecutive days. Control mice were similarly instilled with vehicle (0.9% NaCl). Instillation of dust increased expression of Saa3 statistically significantly, 6-fold for storage hall dust and 11-fold for boiler room dust (Table 3).

**Correlation between pulmonary Saa3 expression and neutrophil influx**

SAA is known to be a neutrophil chemoattractant [37]. In all studies, neutrophil levels in BALF were assessed [20,22,23,31,32], enabling analysis of the correlation between Saa3 expression levels and the number of neutrophil cell. We found a robust correlation across particle type, method of administration, dose, and time after exposure (Figure 3).

**Discussion**

We show that pulmonary exposure to a variety of nanomaterials and other particles results in a rapid and long lasting increase of Saa3 mRNA levels in lung tissue. This was accompanied by elevated SAA3 protein levels in BAL fluid and in plasma in MWCNT exposed mice. Pulmonary Saa3 expression co-varied with neutrophil influx in lung lining fluid across particle types, dosing regimens, doses and time points. Only small changes in hepatic expression of Saa3 were observed. This indicates that pulmonary deposition of particulate matter, including nanoparticles, induces a pulmonary acute phase response. The pulmonary acute phase response correlated closely with neutrophil influx in lung lining fluid.

It is a generally held view that pulmonary inflammation and release of cytokines into the circulation result in a hepatic acute phase response. In contrast, we found a stronger acute phase response in lung than in liver. For most exposures, we only detected increased expression of acute phase protein in lung tissue, whereas for NanoCB, we have previously reported increased expression of the acute phase proteins Saa3, Omr3 and Saa1 in liver tissue 24 hours after instillation of 162 μg NanoCB/mouse and increased expression of Gip 28 after exposure [23]. We also found increased Saa3 expression in liver 28 days after inhalation exposure to NanoCB (Table 4). However, we consistently found the strongest acute phase response in lung tissue, both in terms of the observed induction fold and in terms of number of differentially expressed acute phase genes.

We used Saa3 mRNA levels as a biomarker of a pulmonary acute phase response. We have previously found increased expression up to 43 acute phase genes in lung tissue in analyses of global gene expression following pulmonary exposure to NanoCB and NanoTiO2 [19,25,26]. Signal molecules like cytokines and acute phase proteins are regulated at the level of transcription and the proteins subsequently go into systemic circulation. Therefore increased mRNA expression is the best
Table 3. Relative Saa3 mRNA levels in lung and liver tissue after pulmonary deposition of particles.

<table>
<thead>
<tr>
<th>Particle</th>
<th>Study</th>
<th>Exposure set-up</th>
<th>Reference</th>
<th>Liver Control</th>
<th>Liver Exposed</th>
<th>Lung Control</th>
<th>Lung Exposed</th>
</tr>
</thead>
<tbody>
<tr>
<td>NanoCB</td>
<td>3</td>
<td>Inhalation: 4×1.5 h ×20 mg/m³</td>
<td>[32]</td>
<td>25±37</td>
<td>19±7.8</td>
<td>25±30</td>
<td>111±63*</td>
</tr>
<tr>
<td>DEP</td>
<td>3</td>
<td>Inhalation: 4×1.5 h ×20 mg/m³</td>
<td>[32]</td>
<td>25±37</td>
<td>38±16</td>
<td>25±30</td>
<td>435±662*</td>
</tr>
<tr>
<td>Boiler dust</td>
<td>6</td>
<td>Intratracheal instillation: 4×54 µg</td>
<td>[31]</td>
<td>ND†</td>
<td>ND†</td>
<td>563±540</td>
<td>3337±3006*</td>
</tr>
<tr>
<td>Straw dust</td>
<td>6</td>
<td>Intratracheal instillation: 4×54 µg</td>
<td>[31]</td>
<td>ND†</td>
<td>ND†</td>
<td>563±540</td>
<td>6389±5520*</td>
</tr>
</tbody>
</table>

Saa3 mRNA levels were normalised to 18S and multiplied by 10⁷. Mean±SD is shown. * p<0.001 compared to controls. † Not determined.

doi:10.1371/journal.pone.0069020.t003

Table 4. Relative Saa3 mRNA levels in lung and liver tissue after pulmonary deposition of particles by inhalation.

<table>
<thead>
<tr>
<th>Particle</th>
<th>Study</th>
<th>Exposure set-up</th>
<th>Reference</th>
<th>4–5 days after exposure</th>
<th>~4 weeks after exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Liver Control</td>
<td>Exposed</td>
</tr>
<tr>
<td>NanoTiO₂</td>
<td>4</td>
<td>11×1 h ×42 mg/m³</td>
<td>[23]</td>
<td>201±336</td>
<td>70±51</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(330±376)‡</td>
<td>(2384±1722)‡</td>
</tr>
<tr>
<td>NanoCB</td>
<td>5</td>
<td>11×1 h ×42 mg/m³</td>
<td>[22]</td>
<td>52±27</td>
<td>116±48</td>
</tr>
</tbody>
</table>

Saa3 mRNA levels were normalised to 18S and multiplied by 10⁷. Mean±SD is shown. * p<0.05, † p<0.01, ‡ p<0.001, 1 One outlier has been removed in each group.

doi:10.1371/journal.pone.0069020.t004
However, these studies were long lasting, used large groups of transgenic mice and had a small dynamic range. They allowed for demonstration of effect but did not allow for comparison of atherosclerotic effect of different particles. The use of biomarkers of the acute phase response has been complicated by the fact that inhalation of particles was not accompanied by a hepatic acute phase response [24]. The presented results indicate that pulmonary $Saa3$ expression may be used as a biomarker that allows for comparison of the cardiovascular toxicity of different particles and nanomaterials in wildtype animal models. Furthermore, the large dynamic range increases sensitivity, thus reducing the number of animals needed to detect an effect.

In the mice inhaling DEP and NanoCB for 90 min for 4 consecutive days (Study 3), pulmonary expression of $\text{Il-6}$ and $\text{Tnf}$ was increased, but to a similar degree by NanoCB and DEP while $\text{Il1}\beta$ mRNA expression was low and unaffected by exposure [32]. However, the influx of neutrophils was very different for the two exposures. In DEP exposed mice, the percentage of neutrophils in BALF cells was increased from 4% in controls to 15% in DEP exposed, whereas no increase in neutrophils was observed in mice exposed to NanoCB [32]. Pulmonary $Saa3$ gene expression covaried with the neutrophil influx, since $Saa3$ expression was 4 times higher in DEP exposed mice than in NanoCB exposed mice. Because $\text{Il1}\beta$, $\text{Il6}$ and $\text{Tnf}$ expression levels were comparable for the two exposures, it appears as if the neutrophil influx is more closely associated with $Saa3$ expression levels. SAA is a chemoattractant for neutrophils, and the chemoattractant effect of SAA is blocked when SAA forms complexes with HDL [37]. It has previously been demonstrated that macrophages secrete SAA [56]. We suggest that nanoparticles stimulate macrophages to secrete SAA which acts as an important chemoattractant for neutrophils. This would link pulmonary particle exposure directly with cardiovascular disease. Many other cytokines are chemoattractants for neutrophils [57].

In controlled human exposure studies, exposure to ambient particulate matter increased blood levels of the acute phase protein CRP [58]. Ambient PM(2.5) has been associated with increased blood levels of CRP [39–62], and blood levels of SAA were increased in volunteers exposed to wood smoke [63]. In a cross-sectional study of serum levels of CRP and SAA, LDL and triglyceride levels were positively associated with CRP levels and HDL levels correlated negatively with CRP, although the latter association was not statistically significant. No associations between serum levels of SAA and HDL, LDL or triglycerides were observed [64]. When humans undergo acute phase response, LDL synthesis is increased, but LDL levels in blood decrease due to up-regulation of LDL receptor activity [65]. HDL blood levels decrease, and blood levels of triglycerides increase [65]. Patients with acute myocardial infarction also undergo an acute phase response. Cholesterol biosynthesis was assessed in 34 patients hospitalised with acute myocardial infarction and cholesterol biosynthesis was found to be 23 and 29% increased 1 and 2 days after hospitalisation, respectively [66]. Thus, the observed increased cholesterol content in liver and lowered serum HDL levels observed in mice following pulmonary exposure to NanoCB [25] is similar to what is observed in humans.

Given the close association between acute phase response and risk of cardiovascular disease, our results indicate that exposures to NanoCB and NanoTiO$_2$ at doses which are comparable to 3 or 14 working days at the current Danish occupational exposure limits of 3.5 mg/m$^3$ for CB and 9.75 mg/m$^3$ for TiO$_2$, respectively [20,21] lead to increased $Saa3$ expression even 28 days after last exposure. Similar results were obtained after 11 days inhalation of NanoCB.
and NanoTiO$_2$ at doses corresponding to 1.5 or 0.5 times the current Danish occupational exposure limits. Also dust collected in a biofuel facility with high exposure to both particles and endotoxins increased Saa3 levels in lungs of exposed mice [31]. Human exposure levels at this plant were 0.62 mg/m$^3$ dust and 1298 EU/m$^3$ endotoxin in the storage hall and 1.18 mg/m$^3$ dust and 2178 EU/m$^3$ endotoxin in the boiler room [31]. The 4 times 54 mg/kg/animal administered to the animals over 4 days corresponded to 2 weeks of exposure [31].

Conclusions

Pulmonary exposure to several nanomaterials and other particles led to a pulmonary acute phase response characterised by long-lasting increased expression of Saa3 mRNA and plasma SAA3 protein. SAA has a key role in promotion of plaque progression. We therefore propose that the pulmonary acute phase response may constitute a causative link between particle inhalation and risk of cardiovascular disease. The SAA is a potent chemotactic factor for neutrophils and the mRNA levels of Saa3 correlated closely with the number of neutrophils in BAL fluid across exposure type, dose and time after exposure and particle type. Our results suggest that nanoparticles differ in their ability to induce acute phase response and therefore that evaluation of the potency to induce pulmonary acute phase response may allow for the rating of different nanoparticles in relation to risk of cardiovascular disease.

Acknowledgments

The technical assistance from Lourdes Pedersen, Elsbjært Christiansen, Anne-Karin Jensen, Michael Goldbrandsen, Signe H. Nielsen and Lars Bentzen is gratefully acknowledged.

Author Contributions

Conceived and designed the experiments: ATS UBV HW KSH NRJ. Performed the experiments: NRJ JFL JSL GRH ANN AMM PW. Analyzed the data: ATS UBV HW JSL GRH. Wrote the paper: ATS JSL UBV HW.

References


